Cargando…
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor
BACKGROUND: KRAS is mutated in ∼30% of non-small-cell lung cancer (NSCLC) but it has also been identified as one of the mechanisms underlying resistance to tyrosine kinase inhibitors (TKIs) in EGFR-positive NSCLC patients. Novel KRAS inhibitors targeting KRAS p.G12C mutation have been developed rece...
Autores principales: | Serna-Blasco, R., Sánchez-Herrero, E., Sanz-Moreno, S., Rodriguez-Festa, A., García-Veros, E., Casarrubios, M., Sierra-Rodero, B., Laza-Briviesca, R., Cruz-Bermúdez, A., Mielgo-Rubio, X., Sánchez-Hernández, A., Uribelarrea, E.A., Calvo, V., Romero, A., Provencio, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493588/ https://www.ncbi.nlm.nih.gov/pubmed/34607284 http://dx.doi.org/10.1016/j.esmoop.2021.100279 |
Ejemplares similares
-
The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy
por: Cruz-Bermúdez, Alberto, et al.
Publicado: (2021) -
Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013) -
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
por: Romero, Atocha, et al.
Publicado: (2020) -
Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022) -
Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation
por: Serna-Blasco, Roberto, et al.
Publicado: (2022)